B
Bullisch
Bullisch · 25%LH
$255.84
Szenariopreis
$328.950
-0.987 (-0.30%)Zum Schluss
Loading chart…
- Hoch
- 331.565
- Eröffnung
- 327.090
- Volumengewichteter Durchschnittskurs
- 329.12
- Volumen
- 663.98K
- Marktkap.
- 17.27B
- Tief
- 326.830
- Umsatz
- 218.53M
- EV/EBITDA, TTM
- 12.89
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
KI-Analyse of Labcorp Holdings Inc (LH)
KaufenLaboratory Corporation of America Holdings (LH) is a good buy right now due to its current price of $328.95 being below the analyst price targets of $365 and $380, suggesting significant upside potential. The forward P/E ratio of 16.16 indicates that the stock is reasonably valued compared to its expected earnings growth. Additionally, the gross margin of 27.71% in the latest quarter reflects strong profitability. However, a key risk to consider is the rising inflation concerns that could impact market sentiment, as indicated by the recent news on market risks.
Analystenbewertungen (19)
-7.45% Abwärtspotenzial
Kaufen
13 Kaufen
6 Halten
0 Verkaufen
Aktuell: 328.95
Tief
270.00
Durchschnitt
304.45
Hoch
325.00
Truist
Kaufen
$365
2026-09-21
Truist
2026-09-21
Kursziel
$365
Kaufen
UBS
Kaufen
$380
2026-09-11
UBS
2026-09-11
Kursziel
$380
Kaufen
Barclays
Equal Weight
$330
2026-09-11
Barclays
2026-09-11
Kursziel
$330
Equal Weight
Mizuho
Überdurchschnittlich
$355
2026-08-10
Mizuho
2026-08-10
Kursziel
$355
Überdurchschnittlich
Piper Sandler
Neutral
$309
2026-08-04
Piper Sandler
2026-08-04
Kursziel
$309
Neutral
Bewertungskennzahlen
Das aktuelle erwartete KGV von Labcorp Holdings Inc (LH) beträgt 16.16, verglichen mit dem 5-Jahres-Durchschnitt von 14.97.
Alphio-AI-Kursszenarien für LH
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die LH halten
Event-Zeitleiste
News
9.510-23CNBCMajor Risks Loom for Stock Market Next Week Amid AI Trade Stumbles
8.510-23NewsfilterLabcorp to Launch FDA-Approved HPV Testing by Late 2026
7.510-22PRnewswireLabcorp Collaborates with FDA to Enhance Drug Abuse Assessment Science
7.510-22NewsfilterLabcorp Collaborates with FDA to Assess Drug Abuse Potential
8.010-21PRnewswireLabcorp Declares $0.72 Cash Dividend Per Share
LH FAQ – beantwortet von Alphio AI
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
Laboratory Corporation of America Holdings (LH) is a good buy right now due to its current price of $328.95 being below the analyst price targets of $365 and $380, suggesting significant upside potential. The forward P/E ratio of 16.16 indicates that the stock is reasonably valued compared to its expected earnings growth. Additionally, the gross margin of 27.71% in the latest quarter reflects strong profitability. However, a key risk to consider is the rising inflation concerns that could impact market sentiment, as indicated by the recent news on market risks.
19 analysts cover LH: 13 rate it Buy, 6 Hold and 0 Sell. The average price target is 304.45.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.